Minister Hodgson completes successful B.C. trip focused on advancing nation-building in partnership with Indigenous Peoples

Minister Tim Hodgson completed a trip to British Columbia to advance reconciliation and promote Indigenous ownership in the province's natural resource and energy sectors

Justin Tomlinson

Editor-in-Chief, Mora Discover

4 sources
Minister Hodgson completes successful B.C. trip focused on advancing nation-building in partnership with Indigenous Peoples

Minister Tim Hodgson concluded a visit to British Columbia on May 15, 2026, emphasizing a new era of nation-building centered on partnerships with Indigenous Peoples. The visit focused on transforming the federal government's relationship with Indigenous communities by prioritizing collaboration and consultation. This approach aims to place Indigenous ownership at the heart of natural resource development as part of a once-in-a-generation effort to build a stronger and more secure nation.[1][2][3][4]

British Columbia is uniquely positioned to lead Canada's energy superpower ambitions due to its ambitious energy goals and world-leading mineral deposits. The province features a vast forest products ecosystem, a clean electricity grid, and a talented workforce. Additionally, its short shipping times to key Asian markets and established Indigenous partnerships at the forefront of major project development provide a strategic advantage for national economic growth.[1][4]

The federal strategy seeks to fundamentally transform the relationship with Indigenous Peoples through a historic opportunity for reconciliation. By focusing on Indigenous leadership in the natural resource sector, the government intends to foster a more sovereign nation. This collaborative framework is designed to ensure that major projects benefit from local expertise and consultation while advancing Canada's broader energy and resource objectives on the global stage.[1][3][4]

Related stories

Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed
Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed
Investorplace

Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In today's Market 360, I’ll explain the connection between Bessent and Warsh – and why I think it’s good news for investors. I’ll also give you my prediction for the Fed’s next move and how to be positioned before everyone else catches on. The post Here’s Why Everyone’s Wrong About What’s About to Happen at the Fed appeared first on InvestorPlace .

Fiscal policy drives growth
Fiscal policy drives growth
Báo Nhân Dân Điện Tử

Fiscal policy drives growth

Promoting growth will be one of the top priorities in Viet Nam’s economic development and policy planning in 2026. This will contribute to achieving double-digit growth targets in the 2026-2030 period and beyond. An urgent fiscal measure to cool domestic prices PM outlines key tasks, solutions for monetary, fiscal policy management in 2026 2026 state budget: Strengthening fiscal policy to fuel long-term growth

Monopar Therapeutics Reports Q1 2026 Results and Wilson Disease Program Progress
Monopar Therapeutics Reports Q1 2026 Results and Wilson Disease Program Progress
Benzinga

Monopar Therapeutics Reports Q1 2026 Results and Wilson Disease Program Progress

WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ: MNPR ), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates. Recent Program Developments ALXN1840 for Wilson Disease – NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at the American Academy of Neurology (AAN) Annual Meeting 2026. The late-breaker oral and poster presentation, titled "Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 F

Synthesized from 3 sources